Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity - podcast episode cover

Harlan Robins on How T-cell Focused COVID Vaccines Can Move Us Toward Endemicity

Feb 16, 202231 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Harlan Robins is the Chief Scientific Officer at Adaptive Biotechnologies in Seattle. In 2014, Harlan and his brother Chad co-founded Adaptive as a spinout from the Fred Hutchinson Cancer Center where Harlan had served as the head of computational biology. Adaptive has been developing what they call "immune medicine" mainly in the area of cancer. When the corona virus pandemic hit, they came out with the world’s first T cell-based COVID diagnostic. The test has garnered them a lot of data on T cell response to COVID.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
For the best experience, listen in Metacast app for iOS or Android